Perrigo Company plc (PRGO) Gross Margin
- Gross margin · 12 months: Value 33.26%; Formula and calculation Gross profit / revenue. Period ending 2026-06-27..
Gross margin
Overview →Financial period ending 2026-06-27; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | 33.26% | Gross profit / revenue. Period ending 2026-06-27. $1.38B ÷ $4.14B × 100 ≈ 33.26% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | 1.38B USD | Gross Profit |
| Revenue | 4.14B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 2.77B USD | Cost of Goods and Services Sold |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-06-27 | $1.38B | $4.14B | $2.77B | 33.26% |
| 2026-03-28 | $1.43B | $4.18B | $2.75B | 34.17% |
| 2025-12-31 | $1.49B | $4.25B | $2.76B | 35.14% |
| 2025-09-27 | $1.52B | $4.28B | $2.76B | 35.46% |
| 2025-06-28 | $1.55B | $4.33B | $2.78B | 35.73% |
| 2025-03-29 | $1.58B | $4.34B | $2.76B | 36.38% |
| 2024-12-31 | $1.54B | $4.37B | $2.83B | 35.27% |
| 2024-09-28 | $1.58B | $4.39B | $2.81B | 36.07% |
| 2024-06-29 | $1.59B | $4.43B | $2.84B | 35.93% |
| 2024-03-30 | $1.62B | $4.56B | $2.93B | 35.65% |
| 2023-12-31 | $1.68B | $4.66B | $2.98B | 36.09% |
| 2023-09-30 | $1.64B | $4.65B | $3.02B | 35.15% |
| 2023-07-01 | $1.59B | $4.63B | $3.04B | 34.28% |
| 2023-04-01 | $1.53B | $4.56B | $3.03B | 33.59% |
| 2022-12-31 | $1.46B | $4.45B | $3.00B | 32.69% |
| 2022-10-01 | $1.44B | $4.40B | $2.97B | 32.61% |
| 2022-07-02 | $1.41B | $4.34B | $2.94B | 32.43% |
| 2022-04-02 | $1.39B | $4.20B | $2.82B | 32.97% |
| 2021-12-31 | $1.42B | $4.14B | $2.72B | 34.22% |
| 2021-10-02 | $1.76B | $5.06B | $3.30B | 34.74% |
| 2021-07-03 | $1.79B | $5.02B | $3.23B | 35.67% |
| 2021-04-03 | (m) | (m) | $3.20B | (m) |
| 2020-12-31 | $1.82B | $5.06B | $3.25B | 35.85% |
| 2020-09-30 | $1.83B | $5.10B | (m) | 35.85% |
| 2020-09-26 | $1.83B | $5.10B | $3.27B | 35.84% |
| 2020-06-30 | $1.81B | $5.07B | (m) | 35.70% |
| 2020-06-27 | $1.81B | $5.07B | $3.26B | 35.70% |
| 2020-03-31 | $1.81B | $5.00B | (m) | 36.13% |
| 2020-03-28 | $1.81B | $5.00B | $3.20B | 36.13% |
| 2019-12-31 | $1.77B | $4.84B | $3.06B | 36.66% |
| 2019-09-28 | $1.74B | $4.71B | $2.97B | 36.85% |
| 2019-06-29 | $1.75B | $4.65B | $2.90B | 37.56% |
| 2019-03-30 | $1.79B | $4.69B | $2.90B | 38.12% |
| 2018-12-31 | $1.83B | $4.73B | $2.90B | 38.71% |
| 2018-09-29 | $1.90B | $4.82B | $2.92B | 39.45% |
| 2018-06-30 | $1.97B | $4.92B | $2.94B | 40.15% |
| 2018-03-31 | $2.01B | $4.97B | $2.96B | 40.40% |
| 2017-12-31 | $1.98B | $4.95B | $2.97B | 40.02% |
| 2017-09-30 | $1.95B | $4.99B | $3.04B | 39.13% |
| 2017-07-01 | $1.94B | $5.02B | $3.08B | 38.63% |
| 2017-04-01 | $1.98B | $5.13B | $3.14B | 38.68% |
| 2016-12-31 | $2.05B | $5.28B | $3.23B | 38.86% |
| 2016-10-01 | $2.16B | $5.64B | (m) | 38.20% |
| 2016-07-02 | $2.20B | $5.63B | (m) | 39.02% |
| 2016-04-02 | $2.26B | $5.68B | (m) | 39.74% |
| 2015-12-31 | $2.12B | $5.35B | (m) | 39.53% |
| 2015-09-26 | $1.94B | $5.00B | (m) | 38.81% |
| 2015-06-27 | $1.71B | $4.60B | (m) | 37.20% |
| 2015-03-28 | $1.50B | $4.22B | $2.72B | 35.58% |
| 2014-12-27 | $1.44B | $4.17B | $2.74B | 34.43% |
| 2014-09-27 | $1.41B | $4.08B | $2.67B | 34.65% |
| 2014-06-28 | $1.45B | $4.06B | $2.61B | 35.65% |
| 2014-03-29 | (m) | (m) | (m) | (m) |
| 2013-12-28 | (m) | (m) | (m) | (m) |
| 2013-09-28 | (m) | (m) | (m) | (m) |
| 2013-06-29 | $1.28B | $3.54B | $2.26B | 36.16% |
| 2013-03-30 | (m) | (m) | (m) | (m) |
| 2012-12-29 | (m) | (m) | (m) | (m) |
| 2012-09-29 | (m) | (m) | (m) | (m) |
| 2012-06-30 | $1.10B | $3.17B | $2.08B | 34.53% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |